Squarepoint’s Marker Therapeutics MRKR Stock Holding History

Squarepoint’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-43,302	Closed	-$53.3K	–	4846
2025 Q1	$53.3K	Buy	+43,302	New	+$79.3K	﹤0.01%	4334
2021 Q2	–	Sell	-1,086	Closed	-$24K	–	3527
2021 Q1	$24K	Sell	1,086 -1,940	-64%	-$44.4K	﹤0.01%	3023
2020 Q4	$44K	Buy	+3,026	New	+$47K	﹤0.01%	2810
2020 Q2	–	Sell	-1,324	Closed	-$25K	–	2413
2020 Q1	$25K	Buy	1,324 +60	+5%	+$1.53K	﹤0.01%	1769
2019 Q4	$36K	Buy	+1,264	New	+$46K	﹤0.01%	2411
2019 Q2	–	Sell	-2,256	Closed	-$149K	–	2566
2019 Q1	$149K	Buy	+2,256	New	+$132K	﹤0.01%	1993

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Squarepoint's MRKR Position: Q2 2025 in Review

Squarepoint sold out of Marker Therapeutics (MRKR) in Q2 2025, closing a stake of 43,302 shares — an estimated $53.3K sold.

Squarepoint first reported a position in MRKR in Q1 2019 and held it in 6 quarters. The position peaked at $149K in Q1 2019. 31 funds tracked by Wall St. Rank hold MRKR as of Q2 2025.

Squarepoint reported no remaining Marker Therapeutics position as of Q2 2025 after selling out during the quarter.
Squarepoint sold 43,302 Marker Therapeutics shares in Q2 2025, an estimated $53.3K.
Squarepoint first reported a position in Marker Therapeutics in Q1 2019 and held it in 6 quarters.
Squarepoint's Marker Therapeutics position peaked at $149K in Q1 2019.
31 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.